Keywords
Last Name
Institution

SAROJ VADHAN

TitleProfessor
InstitutionMD Anderson
DepartmentSarcoma Medical Oncology
Address1515 Holcombe Blvd.
Houston TX 77030
vCardDownload vCard

    Collapse Additional Tools and Researcher Information 
    Collapse Verify Publications

    Collapse Bibliographic 
    Collapse selected publications
    Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Faculty can login to make corrections and additions.
    List All   |   Timeline
    1. Vadhan-Raj S, Goldberg JD, Perales MA, Berger DP, van den Brink MR. Clinical applications of palifermin: amelioration of oral mucositis and other potential indications. J Cell Mol Med. 2013 Nov; 17(11):1371-84. PMID: 24251854.
      View in: PubMed
    2. Henry D, Vadhan-Raj S, Hirsh V, von Moos R, Hungria V, Costa L, Woll PJ, Scagliotti G, Smith G, Feng A, Jun S, Dansey R, Yeh H. Delaying skeletal-related events in a randomized phase 3 study of denosumab versus zoledronic acid in patients with advanced cancer: an analysis of data from patients with solid tumors. Support Care Cancer. 2014 Mar; 22(3):679-87. PMID: 24162260.
      View in: PubMed
    3. Crawford J, Armitage J, Balducci L, Becker PS, Blayney DW, Cataland SR, Heaney ML, Hudock S, Kloth DD, Kuter DJ, Lyman GH, McMahon B, Rugo HS, Saad AA, Schwartzberg LS, Shayani S, Steensma DP, Talbott M, Vadhan-Raj S, Westervelt P, Westmoreland M, Dwyer M, Ho M. Myeloid growth factors. J Natl Compr Canc Netw. 2013 Oct 1; 11(10):1266-90. PMID: 24142827.
      View in: PubMed
    4. Vadhan-Raj S, Strauss W, Ford D, Bernard K, Boccia R, Li J, Allen LF. Efficacy and safety of IV ferumoxytol for adults with iron deficiency anemia previously unresponsive to or unable to tolerate oral iron. Am J Hematol. 2014 Jan; 89(1):7-12. PMID: 23983177; PMCID: PMC4223995.
    5. Raj SD, Zhou X, Bueso-Ramos CE, Ravi V, Patel S, Benjamin RS, Vadhan-Raj S. Prognostic significance of elevated D-dimer for survival in patients with sarcoma. Am J Clin Oncol. 2012 Oct; 35(5):462-7. PMID: 21654313.
      View in: PubMed
    6. Kanagal-Shamanna R, Zhao W, Vadhan-Raj S, Nguyen MH, Fernandez MH, Medeiros LJ, Bueso-Ramos CE. Over-expression of CYP2E1 mRNA and protein: implications of xenobiotic induced damage in patients with de novo acute myeloid leukemia with inv(16)(p13.1q22); CBF?-MYH11. Int J Environ Res Public Health. 2012 Aug; 9(8):2788-800. PMID: 23066397; PMCID: PMC3447587.
    7. Vadhan-Raj S, von Moos R, Fallowfield LJ, Patrick DL, Goldwasser F, Cleeland CS, Henry DH, Novello S, Hungria V, Qian Y, Feng A, Yeh H, Chung K. Clinical benefit in patients with metastatic bone disease: results of a phase 3 study of denosumab versus zoledronic acid. Ann Oncol. 2012 Dec; 23(12):3045-51. PMID: 22851406.
      View in: PubMed
    8. Arun BK, Dhinghra K, Valero V, Kau SW, Broglio K, Booser D, Guerra L, Yin G, Walters R, Sahin A, Ibrahim N, Buzdar AU, Frye D, Sneige N, Strom E, Ross M, Theriault RL, Vadhan-Raj S, Hortobagyi GN. Phase III randomized trial of dose intensive neoadjuvant chemotherapy with or without G-CSF in locally advanced breast cancer: long-term results. Oncologist. 2011; 16(11):1527-34. PMID: 22042783.
      View in: PubMed
    9. Kanagal-Shamanna R, Bueso-Ramos CE, Barkoh B, Lu G, Wang S, Garcia-Manero G, Vadhan-Raj S, Hoehn D, Medeiros LJ, Yin CC. Myeloid neoplasms with isolated isochromosome 17q represent a clinicopathologic entity associated with myelodysplastic/myeloproliferative features, a high risk of leukemic transformation, and wild-type TP53. Cancer. 2012 Jun 1; 118(11):2879-88. PMID: 22038701.
      View in: PubMed
    10. Vadhan-Raj S, Fayad LE, Fanale MA, Pro B, Rodriguez A, Hagemeister FB, Bueso-Ramos CE, Zhou X, McLaughlin PW, Fowler N, Shah J, Orlowski RZ, Samaniego F, Wang M, Cortes JE, Younes A, Kwak LW, Sarlis NJ, Romaguera JE. A randomized trial of a single-dose rasburicase versus five-daily doses in patients at risk for tumor lysis syndrome. Ann Oncol. 2012 Jun; 23(6):1640-5. PMID: 22015451; PMCID: PMC4110463.
    11. Crawford J, Allen J, Armitage J, Blayney DW, Cataland SR, Heaney ML, Htoy S, Hudock S, Kloth DD, Kuter DJ, Lyman GH, McMahon B, Steensma DP, Vadhan-Raj S, Westervelt P, Westmoreland M. Myeloid growth factors. J Natl Compr Canc Netw. 2011 Aug 1; 9(8):914-32. PMID: 21900221.
      View in: PubMed
    12. Henry DH, Costa L, Goldwasser F, Hirsh V, Hungria V, Prausova J, Scagliotti GV, Sleeboom H, Spencer A, Vadhan-Raj S, von Moos R, Willenbacher W, Woll PJ, Wang J, Jiang Q, Jun S, Dansey R, Yeh H. Randomized, double-blind study of denosumab versus zoledronic acid in the treatment of bone metastases in patients with advanced cancer (excluding breast and prostate cancer) or multiple myeloma. J Clin Oncol. 2011 Mar 20; 29(9):1125-32. PMID: 21343556.
      View in: PubMed
    13. Vadhan-Raj S, Zhou X, Sizer K, Lal L, Wang X, Roquemore J, Shi W, Benjamin RS, Lichtiger B. Impact of safety concerns and regulatory changes on the usage of erythropoiesis-stimulating agents and RBC transfusions. Oncologist. 2010; 15(12):1359-69. PMID: 21159724; PMCID: PMC3227922.
    14. Zhou X, Teegala S, Huen A, Ji Y, Fayad L, Hagemeister FB, Gladish G, Vadhan-Raj S. Incidence and risk factors of venous thromboembolic events in lymphoma. Am J Med. 2010 Oct; 123(10):935-41. PMID: 20920696.
      View in: PubMed
    15. Vadhan-Raj S, Trent J, Patel S, Zhou X, Johnson MM, Araujo D, Ludwig JA, O'Roark S, Gillenwater AM, Bueso-Ramos C, El-Naggar AK, Benjamin RS. Single-dose palifermin prevents severe oral mucositis during multicycle chemotherapy in patients with cancer: a randomized trial. Ann Intern Med. 2010 Sep 21; 153(6):358-67. PMID: 20855800.
      View in: PubMed
    16. Vadhan-Raj S. Clinical findings with the first generation of thrombopoietic agents. Semin Hematol. 2010 Jul; 47(3):249-57. PMID: 20620436.
      View in: PubMed
    17. Kasyan A, Medeiros LJ, Zuo Z, Santos FP, Ravandi-Kashani F, Miranda R, Vadhan-Raj S, Koeppen H, Bueso-Ramos CE. Acute erythroid leukemia as defined in the World Health Organization classification is a rare and pathogenetically heterogeneous disease. Mod Pathol. 2010 Aug; 23(8):1113-26. PMID: 20473273.
      View in: PubMed
    18. Liang M, Han X, Vadhan-Raj S, Nguyen M, Zhang YH, Fernandez M, Drakos E, Konoplev SN, Yin CC, Miranda RN, McDonnell TJ, Medeiros LJ, Bueso-Ramos CE. HDM4 is overexpressed in mantle cell lymphoma and its inhibition induces p21 expression and apoptosis. Mod Pathol. 2010 Mar; 23(3):381-91. PMID: 20062013.
      View in: PubMed
    19. Chen W, Konoplev S, Medeiros LJ, Koeppen H, Leventaki V, Vadhan-Raj S, Jones D, Kantarjian HM, Falini B, Bueso-Ramos CE. Cuplike nuclei (prominent nuclear invaginations) in acute myeloid leukemia are highly associated with FLT3 internal tandem duplication and NPM1 mutation. Cancer. 2009 Dec 1; 115(23):5481-9. PMID: 19672946.
      View in: PubMed
    20. Vij R, Horvath N, Spencer A, Taylor K, Vadhan-Raj S, Vescio R, Smith J, Qian Y, Yeh H, Jun S. An open-label, phase 2 trial of denosumab in the treatment of relapsed or plateau-phase multiple myeloma. Am J Hematol. 2009 Oct; 84(10):650-6. PMID: 19714603.
      View in: PubMed
    21. Schmeler KM, Vadhan-Raj S, Ramirez PT, Apte SM, Cohen L, Bassett RL, Iyer RB, Wolf JK, Levenback CL, Gershenson DM, Freedman RS. A phase II study of GM-CSF and rIFN-gamma1b plus carboplatin for the treatment of recurrent, platinum-sensitive ovarian, fallopian tube and primary peritoneal cancer. Gynecol Oncol. 2009 May; 113(2):210-5. PMID: 19264351; PMCID: PMC4261621.
    22. Park HC, Janjan NA, Mendoza TR, Lin EH, Vadhan-Raj S, Hundal M, Zhang Y, Delclos ME, Crane CH, Das P, Wang XS, Cleeland CS, Krishnan S. Temporal patterns of fatigue predict pathologic response in patients treated with preoperative chemoradiation therapy for rectal cancer. Int J Radiat Oncol Biol Phys. 2009 Nov 1; 75(3):775-81. PMID: 19231100; PMCID: PMC3090722.
    23. Vadhan-Raj S. Management of chemotherapy-induced thrombocytopenia: current status of thrombopoietic agents. Semin Hematol. 2009 Jan; 46(1 Suppl 2):S26-32. PMID: 19245931.
      View in: PubMed
    24. Crawford J, Armitage J, Balducci L, Bennett C, Blayney DW, Cataland SR, Dale DC, Demetri GD, Erba HP, Foran J, Freifeld AG, Goemann M, Heaney ML, Htoy S, Hudock S, Kloth DD, Kuter DJ, Lyman GH, Michaud LB, Miyata SC, Tallman MS, Vadhan-Raj S, Westervelt P, Wong MK. Myeloid growth factors. J Natl Compr Canc Netw. 2009 Jan; 7(1):64-83. PMID: 19176207.
      View in: PubMed
    25. Ye D, Garcia-Manero G, Kantarjian HM, Xiao L, Vadhan-Raj S, Fernandez MH, Nguyen MH, Medeiros LJ, Bueso-Ramos CE. Analysis of Aurora kinase A expression in CD34(+) blast cells isolated from patients with myelodysplastic syndromes and acute myeloid leukemia. J Hematop. 2009 Mar; 2(1):2-8. PMID: 19669217.
      View in: PubMed
    26. Cella D, Viswanathan HN, Hays RD, Mendoza TR, Stein KD, Pasta DJ, Foreman AJ, Vadhan-Raj S, Kallich JD. Development of a fatigue and functional impact scale in anemic cancer patients receiving chemotherapy. Cancer. 2008 Sep 15; 113(6):1480-8. PMID: 18642348; PMCID: PMC2587127.
    27. Sun X, Zhang W, Ramdas L, Stivers DN, Jones DM, Kantarjian HM, Estey EH, Vadhan-Raj S, Medeiros LJ, Bueso-Ramos CE. Comparative analysis of genes regulated in acute myelomonocytic leukemia with and without inv(16)(p13q22) using microarray techniques, real-time PCR, immunohistochemistry, and flow cytometry immunophenotyping. Mod Pathol. 2007 Aug; 20(8):811-20. PMID: 17571080.
      View in: PubMed
    28. Crawford J, Althaus B, Armitage J, Balducci L, Bennett C, Blayney DW, Cataland SR, Dale DC, Demetri GD, Erba HP, Foran J, Freifeld AG, Heaney ML, Htoy S, Kloth DD, Lyman GH, Messersmith WA, Michaud LB, Miyata SC, Robbins A, Tallman MS, Vadhan-Raj S, Westervelt P, Wong MK. Myeloid growth factors. Clinical practice guidelines in oncology. J Natl Compr Canc Netw. 2007 Feb; 5(2):188-202. PMID: 17335688.
      View in: PubMed
    29. Bhardwaj A, Sethi G, Vadhan-Raj S, Bueso-Ramos C, Takada Y, Gaur U, Nair AS, Shishodia S, Aggarwal BB. Resveratrol inhibits proliferation, induces apoptosis, and overcomes chemoresistance through down-regulation of STAT3 and nuclear factor-kappaB-regulated antiapoptotic and cell survival gene products in human multiple myeloma cells. Blood. 2007 Mar 15; 109(6):2293-302. PMID: 17164350.
      View in: PubMed
    30. Zhao W, Claxton DF, Medeiros LJ, Lu D, Vadhan-Raj S, Kantarjian HM, Nguyen MH, Bueso-Ramos CE. Immunohistochemical analysis of CBFbeta-SMMHC protein reveals a unique nuclear localization in acute myeloid leukemia with inv(16)(p13q22). Am J Surg Pathol. 2006 Nov; 30(11):1436-44. PMID: 17063086.
      View in: PubMed
    31. Krishnan S, Janjan NA, Skibber JM, Rodriguez-Bigas MA, Wolff RA, Das P, Delclos ME, Chang GJ, Hoff PM, Eng C, Brown TD, Crane CH, Feig BW, Morris J, Vadhan-Raj S, Hamilton SR, Lin EH. Phase II study of capecitabine (Xeloda) and concomitant boost radiotherapy in patients with locally advanced rectal cancer. Int J Radiat Oncol Biol Phys. 2006 Nov 1; 66(3):762-71. PMID: 17011451.
      View in: PubMed
    32. Johnson MR, Del Carpio-Jayo D, Lin P, Giralt S, Anderlini P, Champlin RE, Khouri IF, Vadhan-Raj S, Medeiros LJ, Bueso-Ramos CE. Primary plasma cell leukemia: morphologic, immunophenotypic, and cytogenetic features of 4 cases treated with chemotherapy and stem cell transplantation. Ann Diagn Pathol. 2006 Oct; 10(5):263-8. PMID: 16979517.
      View in: PubMed
    33. Lin EH, Curley SA, Crane CC, Feig B, Skibber J, Delcos M, Vadhan SR, Morris J, Ayers GD, Ross A, Brown T, Rodriguez-Bigas MA, Janjan N. Retrospective study of capecitabine and celecoxib in metastatic colorectal cancer: potential benefits and COX-2 as the common mediator in pain, toxicities and survival? Am J Clin Oncol. 2006 Jun; 29(3):232-9. PMID: 16755175.
      View in: PubMed
    34. Randomized comparison of every-2-week darbepoetin alfa and weekly epoetin alfa for the treatment of chemotherapy-induced anemia: the 20030125 Study Group Trial. J Clin Oncol. 2006 May 20; 24(15):2290-7. PMID: 16710026.
      View in: PubMed
    35. Merzianu M, Jiang L, Lin P, Wang X, Weber DM, Vadhan-Raj S, Nguyen MH, Medeiros LJ, Bueso-Ramos CE. Nuclear BCL-10 expression is common in lymphoplasmacytic lymphoma/Waldenström macroglobulinemia and does not correlate with p65 NF-kappaB activation. Mod Pathol. 2006 Jul; 19(7):891-8. PMID: 16636680.
      View in: PubMed
    36. Chaves J, Huen A, Bueso-Ramos C, Safdar A, Vadhan-Raj S. Aerosolized ribavirin-induced reversible hepatotoxicity in a hematopoietic stem cell transplant recipient with Hodgkin lymphoma. Clin Infect Dis. 2006 Apr 15; 42(8):e72-5. PMID: 16575720.
      View in: PubMed
    37. Crawford J, Althaus B, Armitage J, Blayney DW, Cataland S, Dale DC, Demetri GD, Foran J, Heaney ML, Htoy S, Kloth DD, Lyman GH, Michaud L, Motl S, Vadhan-Raj S, Wong MK. Myeloid growth factors clinical practice guidelines in oncology. J Natl Compr Canc Netw. 2005 Jul; 3(4):540-55. PMID: 16038645.
      View in: PubMed
    38. Vadhan-Raj S, Cohen V, Bueso-Ramos C. Thrombopoietic growth factors and cytokines. Curr Hematol Rep. 2005 Mar; 4(2):137-44. PMID: 15720963.
      View in: PubMed
    39. Bueso-Ramos CE, Rocha FC, Shishodia S, Medeiros LJ, Kantarjian HM, Vadhan-Raj S, Estrov Z, Smith TL, Nguyen MH, Aggarwal BB. Expression of constitutively active nuclear-kappa B RelA transcription factor in blasts of acute myeloid leukemia. Hum Pathol. 2004 Feb; 35(2):246-53. PMID: 14991544.
      View in: PubMed
    40. Bharti AC, Shishodia S, Reuben JM, Weber D, Alexanian R, Raj-Vadhan S, Estrov Z, Talpaz M, Aggarwal BB. Nuclear factor-kappaB and STAT3 are constitutively active in CD138+ cells derived from multiple myeloma patients, and suppression of these transcription factors leads to apoptosis. Blood. 2004 Apr 15; 103(8):3175-84. PMID: 15070700.
      View in: PubMed
    41. Freedman RS, Vadhan-Raj S, Butts C, Savary C, Melichar B, Verschraegen C, Kavanagh JJ, Hicks ME, Levy LB, Folloder JK, Garcia ME. Pilot study of Flt3 ligand comparing intraperitoneal with subcutaneous routes on hematologic and immunologic responses in patients with peritoneal carcinomatosis and mesotheliomas. Clin Cancer Res. 2003 Nov 1; 9(14):5228-37. PMID: 14614003.
      View in: PubMed
    42. Vadhan-Raj S, Patel S, Bueso-Ramos C, Folloder J, Papadopolous N, Burgess A, Broemeling LD, Broxmeyer HE, Benjamin RS. Importance of predosing of recombinant human thrombopoietin to reduce chemotherapy-induced early thrombocytopenia. J Clin Oncol. 2003 Aug 15; 21(16):3158-67. PMID: 12915607.
      View in: PubMed
    43. Vadhan-Raj S, Mirtsching B, Charu V, Terry D, Rossi G, Tomita D, McGuire WP. Assessment of hematologic effects and fatigue in cancer patients with chemotherapy-induced anemia given darbepoetin alfa every two weeks. J Support Oncol. 2003 Jul-Aug; 1(2):131-8. PMID: 15352656.
      View in: PubMed
    44. Elting LS, Cantor SB, Martin CG, Hamblin L, Kurtin D, Rivera E, Vadhan-Raj S, Benjamin RS. Cost of chemotherapy-induced thrombocytopenia among patients with lymphoma or solid tumors. Cancer. 2003 Mar 15; 97(6):1541-50. PMID: 12627519.
      View in: PubMed
    45. Vadhan-Raj S. Future directions with hematopoietic growth factors. J Natl Compr Canc Netw. 2003 Jan; 1 Suppl 1:S96-101. PMID: 19795582.
      View in: PubMed
    46. Wautier JL. Safety and usefulness of autologous cryopreserved platelets. Lancet. 2002 Dec 14; 360(9349):1985. PMID: 12493312.
      View in: PubMed
    47. Mirtsching B, Charu V, Vadhan-Raj S, Colowick AB, Rossi G, Tomita D, McGuire WP. Every-2-week darbepoetin alfa is comparable to rHuEPO in treating chemotherapy-induced anemia. Results of a combined analysis. Oncology (Williston Park). 2002 Oct; 16(10 Suppl 11):31-6. PMID: 12435171.
      View in: PubMed
    48. Vadhan-Raj S, Kavanagh JJ, Freedman RS, Folloder J, Currie LM, Bueso-Ramos C, Verschraegen CF, Narvios AB, Connor J, Hoots WK, Broemeling LD, Lichtiger B. Safety and efficacy of transfusions of autologous cryopreserved platelets derived from recombinant human thrombopoietin to support chemotherapy-associated severe thrombocytopenia: a randomised cross-over study. Lancet. 2002 Jun 22; 359(9324):2145-52. PMID: 12090979.
      View in: PubMed
    49. Elting LS, Martin CG, Kurtin DJ, Cantor SB, Rubenstein EB, Rodriguez S, Kanesan K, Vadhan-Raj S, Benjamin RS. The Bleeding Risk Index: a clinical prediction rule to guide the prophylactic use of platelet transfusions in patients with lymphoma or solid tumors. Cancer. 2002 Jun 15; 94(12):3252-62. PMID: 12115358.
      View in: PubMed
    50. Vadhan-Raj S. Recombinant human thrombopoietin in myelosuppressive chemotherapy. Oncology (Williston Park). 2001 Jul; 15(7 Suppl 8):35-8. PMID: 11497230.
      View in: PubMed
    51. Grazziutti M, Przepiorka D, Rex JH, Braunschweig I, Vadhan-Raj S, Savary CA. Dendritic cell-mediated stimulation of the in vitro lymphocyte response to Aspergillus. Bone Marrow Transplant. 2001 Mar; 27(6):647-52. PMID: 11319596.
      View in: PubMed
    52. Vadhan-Raj S. Clinical experience with recombinant human thrombopoietin in chemotherapy-induced thrombocytopenia. Semin Hematol. 2000 Apr; 37(2 Suppl 4):28-34. PMID: 10831286.
      View in: PubMed
    53. Vadhan-Raj S, Verschraegen CF, Bueso-Ramos C, Broxmeyer HE, Kudelkà AP, Freedman RS, Edwards CL, Gershenson D, Jones D, Ashby M, Kavanagh JJ. Recombinant human thrombopoietin attenuates carboplatin-induced severe thrombocytopenia and the need for platelet transfusions in patients with gynecologic cancer. Ann Intern Med. 2000 Mar 7; 132(5):364-8. PMID: 10691586.
      View in: PubMed
    54. Vadhan-Raj S, Currie LM, Bueso-Ramos C, Livesey SA, Connor J. Enhanced retention of in vitro functional activity of platelets from recombinant human thrombopoietin-treated patients following long-term cryopreservation with a platelet-preserving solution (ThromboSol) and 2% DMSO. Br J Haematol. 1999 Feb; 104(2):403-11. PMID: 10050726.
      View in: PubMed
    55. Prow D, Vadhan-Raj S. Thrombopoietin: biology and potential clinical applications. Oncology (Williston Park). 1998 Nov; 12(11):1597-604, 1607-8; discussion 1611-4. PMID: 9834938.
      View in: PubMed
    56. Benjapibal M, Kudelka AP, Vasuratna A, Edwards CL, Verschraegen CF, Valero V, Vadhan-Raj S, Kavanagh JJ. Docetaxel and cyclophosphamide induced remission in platinum and paclitaxel refractory ovarian cancer. Anticancer Drugs. 1998 Jul; 9(6):577-9. PMID: 9877247.
      View in: PubMed
    57. Vadhan-Raj S. Recombinant human thrombopoietin: clinical experience and in vivo biology. Semin Hematol. 1998 Jul; 35(3):261-8. PMID: 9685172.
      View in: PubMed
    58. Patel SR, Vadhan-Raj S, Burgess MA, Plager C, Papadopolous N, Jenkins J, Benjamin RS. Results of two consecutive trials of dose-intensive chemotherapy with doxorubicin and ifosfamide in patients with sarcomas. Am J Clin Oncol. 1998 Jun; 21(3):317-21. PMID: 9626808.
      View in: PubMed
    59. Murray LJ, Luens KM, Estrada MF, Bruno E, Hoffman R, Cohen RL, Ashby MA, Vadhan-Raj S. Thrombopoietin mobilizes CD34+ cell subsets into peripheral blood and expands multilineage progenitors in bone marrow of cancer patients with normal hematopoiesis. Exp Hematol. 1998 Mar; 26(3):207-16. PMID: 9502616.
      View in: PubMed
    60. Glisson B, Komaki R, Lee JS, Shin DM, Fossella F, Murphy WK, Kurie J, Perez-Soler R, Schea R, Vadhan-Raj S. Integration of filgrastim into chemoradiation for limited small cell lung cancer: a Phase I study. Int J Radiat Oncol Biol Phys. 1998 Jan 15; 40(2):331-6. PMID: 9457817.
      View in: PubMed
    61. Jones DV, Ashby M, Vadhan-Raj S, Somlo G, Champlin R, Gajewski J, Hellmann S, Fyfe G. Recombinant human thrombopoietin clinical development. Stem Cells. 1998; 16 Suppl 2:199-206. PMID: 11012192.
      View in: PubMed
    62. Patel SR, Vadhan-Raj S, Papadopolous N, Plager C, Burgess MA, Hays C, Benjamin RS. High-dose ifosfamide in bone and soft tissue sarcomas: results of phase II and pilot studies--dose-response and schedule dependence. J Clin Oncol. 1997 Jun; 15(6):2378-84. PMID: 9196153.
      View in: PubMed
    63. Vadhan-Raj S, Murray LJ, Bueso-Ramos C, Patel S, Reddy SP, Hoots WK, Johnston T, Papadopolous NE, Hittelman WN, Johnston DA, Yang TA, Paton VE, Cohen RL, Hellmann SD, Benjamin RS, Broxmeyer HE. Stimulation of megakaryocyte and platelet production by a single dose of recombinant human thrombopoietin in patients with cancer. Ann Intern Med. 1997 May 1; 126(9):673-81. PMID: 9139552.
      View in: PubMed
    64. Glaspy J, Bukowski R, Steinberg D, Taylor C, Tchekmedyian S, Vadhan-Raj S. Impact of therapy with epoetin alfa on clinical outcomes in patients with nonmyeloid malignancies during cancer chemotherapy in community oncology practice. Procrit Study Group. J Clin Oncol. 1997 Mar; 15(3):1218-34. PMID: 9060566.
      View in: PubMed
    65. Reddy SP, Harwood RM, Moore DF, Grimm EA, Murray JL, Vadhan-Raj S. Recombinant interleukin-2 in combination with recombinant interferon-gamma in patients with advanced malignancy: a phase 1 study. J Immunother. 1997 Jan; 20(1):79-87. PMID: 9101417.
      View in: PubMed
    66. Kudelka AP, Termrungruanglert W, Vadhan-Raj S, Edwards CL, Varma DG, Tornos C, Verschraegen CF, Kavanagh JJ. Remission of advanced uterine leiomyosarcoma with pulmonary metastases with carboplatin and paclitaxel. Anticancer Drugs. 1996 Nov; 7(8):885-9. PMID: 8991194.
      View in: PubMed
    67. Verschraegen CF, Kudelka AP, Termrungruanglert W, de Leon CG, Edwards CL, Freedman RS, Kavanagh JJ, Vadhan-Raj S. Effects of interleukin-1 alpha on ovarian carcinoma in patients with recurrent disease. Eur J Cancer. 1996 Aug; 32A(9):1609-11. PMID: 8911126.
      View in: PubMed
    68. Update of recommendations for the use of hematopoietic colony-stimulating factors: evidence-based clinical practice guidelines. American Society of Clinical Oncology. J Clin Oncol. 1996 Jun; 14(6):1957-60. PMID: 8656266.
      View in: PubMed
    69. Murray JL, Kleinerman ES, Jia SF, Rosenblum MG, Eton O, Buzaid A, Legha S, Ross MI, Thompson L, Mujoo K, Rieger PT, Saleh M, Khazaeli MB, Vadhan-Raj S. Phase Ia/Ib trial of anti-GD2 chimeric monoclonal antibody 14.18 (ch14.18) and recombinant human granulocyte-macrophage colony-stimulating factor (rhGM-CSF) in metastatic melanoma. J Immunother Emphasis Tumor Immunol. 1996 May; 19(3):206-17. PMID: 8811495.
      View in: PubMed
    70. Ritchie A, Vadhan-Raj S, Broxmeyer HE. Thrombopoietin suppresses apoptosis and behaves as a survival factor for the human growth factor-dependent cell line, M07e. Stem Cells. 1996 May; 14(3):330-6. PMID: 8724699.
      View in: PubMed
    71. Vadhan-Raj S. Recombinant human erythropoietin in combination with other hematopoietic cytokines in attenuating chemotherapy-induced multilineage myelosuppression: brief communication. Semin Hematol. 1996 Jan; 33(1 Suppl 1):16-8. PMID: 8714611.
      View in: PubMed
    72. Broxmeyer HE, Cooper S, Hague N, Benninger L, Sarris A, Cornetta K, Vadhan-Raj S, Hendrie P, Mantel C. Human chemokines: enhancement of specific activity and effects in vitro on normal and leukemic progenitors and a factor-dependent cell line and in vivo in mice. Ann Hematol. 1995 Nov; 71(5):235-46. PMID: 7492626.
      View in: PubMed
    73. Vadhan-Raj S, Broxmeyer HE, Andreeff M, Bandres JC, Buescher ES, Benjamin RS, Papadopoulos NE, Burgess A, Patel S, Plager C, Hittelman WN, McAlister I, Garrison L, Williams DE. In vivo biologic effects of PIXY321, a synthetic hybrid protein of recombinant human granulocyte-macrophage colony-stimulating factor and interleukin-3 in cancer patients with normal hematopoiesis: a phase I study. Blood. 1995 Sep 15; 86(6):2098-105. PMID: 7662957.
      View in: PubMed
    74. Moore DF, Vadhan-Raj S. Sustained response in Felty's syndrome to prolonged administration of recombinant human granulocyte-macrophage colony-stimulating factor (rhGM-CSF). Am J Med. 1995 Jun; 98(6):591-4. PMID: 7778576.
      View in: PubMed
    75. Broxmeyer HE, Benninger L, Cooper S, Hague N, Benjamin RS, Vadhan-Raj S. Effects of in vivo treatment with PIXY321 (GM-CSF/IL-3 fusion protein) on proliferation kinetics of bone marrow and blood myeloid progenitor cells in patients with sarcoma. Exp Hematol. 1995 Apr; 23(4):335-40. PMID: 7895781.
      View in: PubMed
    76. Anaissie EJ, Vadhan-Raj S. Is it time to redefine the management of febrile neutropenia in cancer patients? Am J Med. 1995 Mar; 98(3):221-3. PMID: 7872336.
      View in: PubMed
    77. Vassilopoulou-Sellin R, Kudelka AP, Kavanagh JJ, Edwards CL, Vadhan-Raj S. Effects of interleukin-1 alpha administration on pituitary-adrenal and pituitary-thyroid axes function of patients with ovarian cancer. J Immunother Emphasis Tumor Immunol. 1995 Feb; 17(2):109-13. PMID: 7647956.
      View in: PubMed
    78. Moore DF, Buescher S, Vadhan-Raj S. Interleukin-1 alpha administration increases oral granulocytes and epithelial cells. J Infect Dis. 1994 Jun; 169(6):1419-20. PMID: 8195637.
      View in: PubMed
    79. Vadhan-Raj S. PIXY321 (GM-CSF/IL-3 fusion protein): biology and early clinical development. Stem Cells. 1994 May; 12(3):253-61. PMID: 8075592.
      View in: PubMed
    80. Vadhan-Raj S, Papadopoulos NE, Burgess MA, Linke KA, Patel SR, Hays C, Arcenas A, Plager C, Kudelka AP, Hittelman WN, et al. Effects of PIXY321, a granulocyte-macrophage colony-stimulating factor/interleukin-3 fusion protein, on chemotherapy-induced multilineage myelosuppression in patients with sarcoma. J Clin Oncol. 1994 Apr; 12(4):715-24. PMID: 8151315.
      View in: PubMed
    81. Vadhan-Raj S, Kudelka AP, Garrison L, Gano J, Edwards CL, Freedman RS, Kavanagh JJ. Effects of interleukin-1 alpha on carboplatin-induced thrombocytopenia in patients with recurrent ovarian cancer. J Clin Oncol. 1994 Apr; 12(4):707-14. PMID: 8151314.
      View in: PubMed
    82. Broxmeyer HE, Benninger L, Patel SR, Benjamin RS, Vadhan-Raj S. Kinetic response of human marrow myeloid progenitor cells to in vivo treatment of patients with granulocyte colony-stimulating factor is different from the response to treatment with granulocyte-macrophage colony-stimulating factor. Exp Hematol. 1994 Jan; 22(1):100-2. PMID: 7506671.
      View in: PubMed
    83. Bodey GP, Anaissie E, Gutterman J, Vadhan-Raj S. Role of granulocyte-macrophage colony-stimulating factor as adjuvant treatment in neutropenic patients with bacterial and fungal infection. Eur J Clin Microbiol Infect Dis. 1994; 13 Suppl 2:S18-22. PMID: 7875147.
      View in: PubMed
    84. Lee AM, Vadhan-Raj S, Hamilton RF, Scheule RK, Holian A. The in vivo effects of rhIL-1 alpha therapy on human monocyte activity. J Leukoc Biol. 1993 Oct; 54(4):314-21. PMID: 8409753.
      View in: PubMed
    85. Buescher ES, McIlheran SM, Banks SM, Vadhan-Raj S. The effects of treatment with PIXY321 (GM-CSF/IL-3 fusion protein) on human polymorphonuclear leukocyte function. Exp Hematol. 1993 Oct; 21(11):1467-72. PMID: 8405227.
      View in: PubMed
    86. Bodey GP, Anaissie E, Gutterman J, Vadhan-Raj S. Role of granulocyte-macrophage colony-stimulating factor as adjuvant therapy for fungal infection in patients with cancer. Clin Infect Dis. 1993 Oct; 17(4):705-7. PMID: 8268354.
      View in: PubMed
    87. Perkins RC, Vadhan-Raj S, Scheule RK, Hamilton R, Holian A. Effects of continuous high dose rhGM-CSF infusion on human monocyte activity. Am J Hematol. 1993 Aug; 43(4):279-85. PMID: 8396850.
      View in: PubMed
    88. Buescher ES, McIlheran SM, Banks SM, Kudelka AP, Kavanagh JJ, Vadhan-Raj S. The effects of interleukin-1 therapy on peripheral blood granulocyte function in humans. Cancer Immunol Immunother. 1993 Jul; 37(1):26-30. PMID: 8513450.
      View in: PubMed
    89. Hamilton RF, Vadhan-Raj S, Uthman M, Grey M, Holian A. The in vivo effects of PIXY321 therapy on human monocyte activity. J Leukoc Biol. 1993 Jun; 53(6):640-50. PMID: 8391053.
      View in: PubMed
    90. Maze R, Horie M, Hendrie P, Vadhan-Raj S, Tricot G, Gordon M, Nemunaitis J, Ashman LK, Broxmeyer HE. Differential responses of myeloid progenitor cells from patients with myeloid leukemia and myelodysplasia to the costimulating effects of steel factor in vitro. Exp Hematol. 1993 Apr; 21(4):545-51. PMID: 7681784.
      View in: PubMed
    91. Arcenas AG, Vadhan-Raj S. Hematopoietic growth factor therapy of myelodysplastic syndromes. Leuk Lymphoma. 1993; 11 Suppl 2:65-9. PMID: 7510197.
      View in: PubMed
    92. Vadhan-Raj S, Broxmeyer HE, Hittelman WN. Use of granulocyte-macrophage colony-stimulating factor in hematopoietic disorders: biology and nature of response. Semin Hematol. 1992 Oct; 29(4 Suppl 3):4-13. PMID: 1492234.
      View in: PubMed
    93. Vadhan-Raj S, Broxmeyer HE, Hittelman WN, Papadopoulos NE, Chawla SP, Fenoglio C, Cooper S, Buescher ES, Frenck RW, Holian A, et al. Abrogating chemotherapy-induced myelosuppression by recombinant granulocyte-macrophage colony-stimulating factor in patients with sarcoma: protection at the progenitor cell level. J Clin Oncol. 1992 Aug; 10(8):1266-77. PMID: 1634916.
      View in: PubMed
    94. Broxmeyer HE, Hangoc G, Cooper S, Ribeiro RC, Graves V, Yoder M, Wagner J, Vadhan-Raj S, Benninger L, Rubinstein P, et al. Growth characteristics and expansion of human umbilical cord blood and estimation of its potential for transplantation in adults. Proc Natl Acad Sci U S A. 1992 May 1; 89(9):4109-13. PMID: 1373894.
      View in: PubMed
    95. Vadhan-Raj S. Clinical trials of granulocyte-macrophage colony-stimulating factor for the treatment of aplastic anemia. Immunol Ser. 1992; 57:661-70. PMID: 1504150.
      View in: PubMed
    96. Broxmeyer HE, Maze R, Miyazawa K, Carow C, Hendrie PC, Cooper S, Hangoc G, Vadhan-Raj S, Lu L. The kit receptor and its ligand, steel factor, as regulators of hemopoiesis. Cancer Cells. 1991 Dec; 3(12):480-7. PMID: 1726456.
      View in: PubMed
    97. Schilling PJ, Vadhan-Raj S. Concurrent cytomegalovirus and pneumocystis pneumonia after fludarabine therapy for chronic lymphocytic leukemia. N Engl J Med. 1990 Sep 20; 323(12):833-4. PMID: 1697401.
      View in: PubMed
    98. Buescher ES, McIlheran SM, Banks SM, Vadhan-Raj S. Alteration of the functional effects of granulocyte-macrophage colony-stimulating factor on polymorphonuclear leukocytes by membrane-fluidizing agents. Infect Immun. 1990 Sep; 58(9):3002-8. PMID: 2167293.
      View in: PubMed
    99. Ventura GJ, Hester JP, Buescher ES, Vadhan-Raj S, Durrett A, Reading CL. Hematopoiesis in limiting dilution cultures: influence of cytokines on human hematopoietic progenitor cells. Exp Hematol. 1990 Sep; 18(8):878-82. PMID: 2201554.
      View in: PubMed
    100. Gutterman J, Vadhan-Raj S, Logothetis C, Anaissle E, Estey E, Talpaz M, Kurzrock R. Effects of granulocyte-macrophage colony-stimulating factor in iatrogenic myelosuppression, bone marrow failure, and regulation of host defense. Semin Hematol. 1990 Jul; 27(3 Suppl 3):15-24. PMID: 2198660.
      View in: PubMed
    101. Hittelman WN, Tigaud JD, Estey E, Vadhan-Raj S. Premature chromosome condensation in the study of minimal residual disease. Bone Marrow Transplant. 1990 Jul; 6 Suppl 1:9-13. PMID: 2202475.
      View in: PubMed
    102. Vadhan-Raj S, Hittelman WN, Lepe-Zuniga JL, Gutterman JU, Broxmeyer HE. Regulation of endogenous erythropoietin levels in anemia associated with myelodysplastic syndromes. Blood. 1990 Apr 15; 75(8):1749-50. PMID: 2183890.
      View in: PubMed
    103. Vadhan-Raj S, Velasquez WS, Butler JJ, LeMaistre A, Lepe-Zuniga J, Keating MJ, Koller CA, Gutterman JU. Stimulation of myelopoiesis in chronic lymphocytic leukemia and in other lymphoproliferative disorders by recombinant human granulocyte-macrophage colony-stimulating factor. Am J Hematol. 1990 Mar; 33(3):189-97. PMID: 2405649.
      View in: PubMed
    104. Vadhan-Raj S, Jeha SS, Buescher S, LeMaistre A, Yee G, Lu L, Lloreta J, Hoots WK, Hittelman WN, Gutterman JU, et al. Stimulation of myelopoiesis in a patient with congenital neutropenia: biology and nature of response to recombinant human granulocyte-macrophage colony-stimulating factor. Blood. 1990 Feb 15; 75(4):858-64. PMID: 2405922.
      View in: PubMed
    105. Ventura GJ, Reading CL, Hester JP, Vadhan-Raj S. Circulating myeloid progenitor cell kinetics during hematologic recovery from chemotherapy and subsequent recombinant human granulocyte-macrophage colony-stimulating factor administration. Acta Haematol. 1990; 84(4):175-81. PMID: 2125781.
      View in: PubMed
    106. Vadhan-Raj S. Clinical applications of colony-stimulating factors. Oncol Nurs Forum. 1989 Nov-Dec; 16(6 Suppl):21-6. PMID: 2687811.
      View in: PubMed
    107. Vadhan-Raj S, Broxmeyer HE, Spitzer G, LeMaistre A, Hultman S, Ventura G, Tigaud JD, Cork MA, Trujillo JM, Gutterman JU, et al. Stimulation of nonclonal hematopoiesis and suppression of the neoplastic clone after treatment with recombinant human granulocyte-macrophage colony-stimulating factor in a patient with therapy-related myelodysplastic syndrome. Blood. 1989 Oct; 74(5):1491-8. PMID: 2676013.
      View in: PubMed
    108. Frenck RW, Buescher ES, Vadhan-Raj S. The effects of recombinant human granulocyte-macrophage colony stimulating factor on in vitro cord blood granulocyte function. Pediatr Res. 1989 Jul; 26(1):43-8. PMID: 2549492.
      View in: PubMed
    109. Broxmeyer HE, Cooper S, Vadhan-Raj S. Cell cycle status of erythroid (BFU-E) progenitor cells from the bone marrows of patients on a clinical trial with purified recombinant human granulocyte-macrophage colony-stimulating factor. Exp Hematol. 1989 Jun; 17(5):455-9. PMID: 2653858.
      View in: PubMed
    110. Ventura GJ, Hester JP, Swan F, Vadhan-Raj S, Turpin J, Dicke KA, Reading CL. Analysis of peripheral blood granulocyte-macrophage colony growth by limiting dilution assay. Exp Hematol. 1989 Feb; 17(2):125-9. PMID: 2643518.
      View in: PubMed
    111. Broxmeyer HE, Vadhan-Raj S. Preclinical and clinical studies with the hematopoietic colony-stimulating factors and related interleukins. Immunol Res. 1989; 8(3):185-201. PMID: 2664033.
      View in: PubMed
    112. Vadhan-Raj S, Hittelman WN, Broxmeyer HE, Keating M, Urdal D, Gutterman JU. In vivo biologic activities of recombinant human granulocyte-macrophage colony-stimulating factor. Ann N Y Acad Sci. 1989; 554:231-40. PMID: 2660675.
      View in: PubMed
    113. Vadhan-Raj S, Buescher S, Broxmeyer HE, LeMaistre A, Lepe-Zuniga JL, Ventura G, Jeha S, Horwitz LJ, Trujillo JM, Gillis S, et al. Stimulation of myelopoiesis in patients with aplastic anemia by recombinant human granulocyte-macrophage colony-stimulating factor. N Engl J Med. 1988 Dec 22; 319(25):1628-34. PMID: 3059191.
      View in: PubMed
    114. Buescher ES, McIlheran SM, Vadhan-Raj S. Effects of in vivo administration of recombinant human granulocyte-macrophage colony-stimulating factor on human neutrophil chemotaxis and oxygen metabolism. J Infect Dis. 1988 Nov; 158(5):1140-2. PMID: 3053927.
      View in: PubMed
    115. Vadhan-Raj S, Cordon-Cardo C, Carswell E, Mintzer D, Dantis L, Duteau C, Templeton MA, Oettgen HF, Old LJ, Houghton AN. Phase I trial of a mouse monoclonal antibody against GD3 ganglioside in patients with melanoma: induction of inflammatory responses at tumor sites. J Clin Oncol. 1988 Oct; 6(10):1636-48. PMID: 3171629.
      View in: PubMed
    116. Vadhan-Raj S, Kellagher MJ, Keating M, Walters R, Gutterman JU. Phase I study of recombinant human granulocyte-macrophage colony-stimulating factor in patients with bone marrow failure and malignancy. Behring Inst Mitt. 1988 Aug; (83):119-24. PMID: 2467646.
      View in: PubMed
    117. Broxmeyer HE, Cooper S, Williams DE, Hangoc G, Gutterman JU, Vadhan-Raj S. Growth characteristics of marrow hematopoietic progenitor/precursor cells from patients on a phase I clinical trial with purified recombinant human granulocyte-macrophage colony-stimulating factor. Exp Hematol. 1988 Aug; 16(7):594-602. PMID: 3260558.
      View in: PubMed
    118. Granulocyte-macrophage colony-stimulating factor and myelodysplastic syndromes. N Engl J Med. 1988 Jul 7; 319(1):51-3. PMID: 3288869.
      View in: PubMed
    119. Vadhan-Raj S, Buescher S, LeMaistre A, Keating M, Walters R, Ventura C, Hittelman W, Broxmeyer HE, Gutterman JU. Stimulation of hematopoiesis in patients with bone marrow failure and in patients with malignancy by recombinant human granulocyte-macrophage colony-stimulating factor. Blood. 1988 Jul; 72(1):134-41. PMID: 3291976.
      View in: PubMed
    120. Ince C, Blick M, Lee M, Pathak S, Vadhan-Raj S, Selvanayagam P, Gutterman JU, Cabanillas F. Bcl-1 gene rearrangements in B cell lymphoma. Leukemia. 1988 Jun; 2(6):343-6. PMID: 3259659.
      View in: PubMed
    121. Pelus LM, Vadhan-Raj S. Modulation of responsiveness of chronic myelogenous leukemia granulocyte-macrophage colony-forming cells to growth regulation following in vivo treatment with recombinant gamma-interferon. Am J Hematol. 1988 May; 28(1):21-6. PMID: 3130750.
      View in: PubMed
    122. Broxmeyer HE, Vadhan-Raj S, Hangoc G, Lu L, Gutterman JU, Williams DE. Preclinical and clinical effects of the hematopoietic colony stimulating factors. Adv Exp Med Biol. 1988; 241:233-41. PMID: 3146907.
      View in: PubMed
    123. Vadhan-Raj S, Keating M, LeMaistre A, Hittelman WN, McCredie K, Trujillo JM, Broxmeyer HE, Henney C, Gutterman JU. Effects of recombinant human granulocyte-macrophage colony-stimulating factor in patients with myelodysplastic syndromes. N Engl J Med. 1987 Dec 17; 317(25):1545-52. PMID: 3500414.
      View in: PubMed
    124. Krown SE, Real FX, Vadhan-Raj S, Oettgen HF. Interferon in AIDS. J Exp Pathol. 1987; 3(4):681-91. PMID: 2457669.
      View in: PubMed
    125. Vadhan-Raj S, Nathan CF, Sherwin SA, Oettgen HF, Krown SE. Phase I trial of recombinant interferon gamma by 1-hour i.v. infusion. Cancer Treat Rep. 1986 May; 70(5):609-14. PMID: 3085930.
      View in: PubMed
    126. Krown SE, Real FX, Vadhan-Raj S, Cunningham-Rundles S, Krim M, Wong G, Oettgen HF. Kaposi's sarcoma and the acquired immune deficiency syndrome. Treatment with recombinant interferon alpha and analysis of prognostic factors. Cancer. 1986 Apr 15; 57(8 Suppl):1662-5. PMID: 3081247.
      View in: PubMed
    127. Vadhan-Raj S, Al-Katib A, Bhalla R, Pelus L, Nathan CF, Sherwin SA, Oettgen HF, Krown SE. Phase I trial of recombinant interferon gamma in cancer patients. J Clin Oncol. 1986 Feb; 4(2):137-46. PMID: 3080551.
      View in: PubMed
    128. Vadhan-Raj S, Wong G, Gnecco C, Cunningham-Rundles S, Krim M, Real FX, Oettgen HF, Krown SE. Immunological variables as predictors of prognosis in patients with Kaposi's sarcoma and the acquired immunodeficiency syndrome. Cancer Res. 1986 Jan; 46(1):417-25. PMID: 2415251.
      View in: PubMed
    129. Nathan CF, Horowitz CR, de la Harpe J, Vadhan-Raj S, Sherwin SA, Oettgen HF, Krown SE. Administration of recombinant interferon gamma to cancer patients enhances monocyte secretion of hydrogen peroxide. Proc Natl Acad Sci U S A. 1985 Dec; 82(24):8686-90. PMID: 3936042; PMCID: PMC391501.
    130. Houghton AN, Mintzer D, Cordon-Cardo C, Welt S, Fliegel B, Vadhan S, Carswell E, Melamed MR, Oettgen HF, Old LJ. Mouse monoclonal IgG3 antibody detecting GD3 ganglioside: a phase I trial in patients with malignant melanoma. Proc Natl Acad Sci U S A. 1985 Feb; 82(4):1242-6. PMID: 3883355; PMCID: PMC397231.
    131. Effects of IV iron treatment with ferumoxytol on health-related quality of life of patients with iron deficiency anemia. Journal of Community and Supportive Oncology. 14:342-350.
    132. Effects of interleukin-la on ovarian carcinoma in patients with recurrent disease. European Journal of Cancer Part A. 32:1598-1602.
    133. Cytokines, GM-CSF and IFNγ administered by priming and post-chemotherapy cycling in recurrent ovarian cancer patients receiving carboplatin. Journal of Translational Medicine. 4.
    134. Hematopoietic growth factors in chemotherapy-induced myelosuppression. Cancer Bulletin. 43:208-214.
    135. Development of the Brief Functional Capacity Tool (BFCT). Journal of Supportive Oncology. 5:10-11.
    136. Erratum. Blood. 122:1325-1326.
    137. Evaluating results from the multiple myeloma patient subset treated with denosumab or zoledronic acid in a randomized phase 3 trial. Blood Cancer Journal. 6.
    138. Safety and efficacy of ferumoxytol for the episodic treatment of iron deficiency anemia in patients with a history of unsatisfactory oral iron therapy. American Journal of Hematology. 91:E3-E5.
    139. Integrating prophylactic measures into practice guidelines. Oncology. 13:593-597.
    140. Mouse monoclonal antibody detecting G(D3) ganglioside.
    141. Evaluation of interleukin-11 (IL-11) in combination with G-CSF administered by different schedules in sarcoma patients receiving adriamycin and ifosfamide (AI) chemotherapy. Blood. 96.
    142. PIXY321 (GM-CSF/IL-3 fusion protein). FORUM - Trends in Experimental and Clinical Medicine. 5:110-118.
    143. Reply to S.M. Sorscher et al. Journal of Clinical Oncology. 29:2736-2737.
    144. Erratum. Clinical Infectious Diseases. 42:1510.
    145. Phenotypic changes induced by recombinant interferon-gamma (r-IFN-γ) therapy in a case of chronic lymphocytic leukemia (CLL).
    146. Expansion of bone marrow progenitors and mobilization of multilineage progenitor cells associated with one-per-cycle administration of the long-acting growth factors pegfilgrastim and darbepoetin alfa with chemotherapy. Journal of Supportive Oncology. 3:22-23.
    147. Efficacy of darbepoetin alfa in the treatment of chemotherapy-induced anemia in non-Hodgkin's lymphoma. Journal of Supportive Oncology. 3:24-25.
    VADHAN's Networks
    Click the "See All" links for more information and interactive visualizations!
    Concepts Expand Description
    _
    Co-Authors Expand Description
    _
    Similar People Expand Description
    _
    Same Department Expand Description